(Q39154516)

9 September 2017

title

Cellular uptake and trafficking of antisense oligonucleotides (English)

1 reference

9 September 2017

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

Stanley T Crooke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Shiyu Wang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Timothy A Vickers

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Wen Shen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

publication date

27 February 2017

1 reference

9 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

230-237

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244996%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nbt.3779

14 June 2020

exact match

0 references

cites work

Antisense oligonucleotides in therapy for neurodegenerative disorders

1 reference

7 January 2021

Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages

1 reference

7 January 2021

Antisense technologies. Improvement through novel chemical modifications

1 reference

7 January 2021

Antisense technology: an emerging platform for cardiovascular disease therapeutics

1 reference

7 January 2021

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

1 reference

7 January 2021

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

1 reference

7 January 2021

Applications of nucleic acid technology in the CNS.

1 reference

7 January 2021

The delivery of therapeutic oligonucleotides

1 reference

7 January 2021

Synthesis, cell-surface binding, and cellular uptake of fluorescently labeled glucose-DNA conjugates with different carbohydrate presentation.

1 reference

7 January 2021

Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides

1 reference

7 January 2021

Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit gene expression in primary embryonic neurons.

1 reference

7 January 2021

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

1 reference

7 January 2021

Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology

1 reference

7 January 2021

Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides

1 reference

7 January 2021

Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis

1 reference

7 January 2021

Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor

1 reference

7 January 2021

Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver

1 reference

7 January 2021

Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides.

1 reference

7 January 2021

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

1 reference

7 January 2021

Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.

1 reference

7 January 2021

Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23/nucleolin

1 reference

7 January 2021

Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells

1 reference

7 January 2021

Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling

1 reference

7 January 2021

Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape

1 reference

7 January 2021

Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.

1 reference

7 January 2021

The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2'-O-methyl modifications

1 reference

7 January 2021

Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity

1 reference

7 January 2021

Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.

1 reference

7 January 2021

Cellular uptake and intracellular trafficking of oligonucleotides

1 reference

7 January 2021

A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism

1 reference

7 January 2021

The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking

1 reference

7 January 2021

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

1 reference

7 January 2021

Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes

1 reference

7 January 2021

Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors

1 reference

7 January 2021

Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis

1 reference

7 January 2021

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

1 reference

7 January 2021

Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides

1 reference

7 January 2021

Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions

1 reference

7 January 2021

Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structures

1 reference

7 January 2021

NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions

1 reference

7 January 2021

Intracellular distribution of microinjected antisense oligonucleotides

1 reference

7 January 2021

Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies

1 reference

7 January 2021

Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

1 reference

7 January 2021

TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells

1 reference

7 January 2021

Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus

1 reference

7 January 2021

Mechanism of oligonucleotide release from cationic liposomes

1 reference

7 January 2021

Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide.

1 reference

7 January 2021

A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells

1 reference

7 January 2021

Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation.

1 reference

7 January 2021

Biological barriers to therapy with antisense and siRNA oligonucleotides

1 reference

7 January 2021

High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides

1 reference

7 January 2021

Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms

1 reference

7 January 2021